PURIFIED CORTROPHIN GEL (repository corticotropin) by ANI Pharmaceuticals is unknown. Approved for exacerbations of multiple sclerosis in adults, acute exacerbations of multiple sclerosis in adults, multiple sclerosis and 3 more indications. First approved in 1954.
Drug data last refreshed 15h ago · AI intelligence enriched 18h ago
Purified Cortrophin Gel is a repository corticotropin (ACTH) injection that stimulates the adrenal cortex to produce cortisol and other corticosteroids. It is indicated for acute exacerbations of multiple sclerosis in adults and rheumatoid arthritis. The mechanism of action involves binding to melanocortin receptors and stimulating adrenal hormone release, though the full pharmacology remains incompletely understood.
Product is in peak commercial phase with stable market position; teams are typically lean given the established, niche indication profile.
unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hypertrophy of the adrenal cortex and continuous high…
Adrenocorticotropic Hormone
Worked on PURIFIED CORTROPHIN GEL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Purified Cortrophin Gel offers stability in a legacy franchise with niche but loyal patient populations; career growth depends on navigating Acthar's competitive pressure and preparing for 2043 LOE. Roles focus on commercial execution, reimbursement defense, and market access rather than clinical development or innovation.